Disease response after TK-DLI according to diagnosis
| Diagnosis . | No. of infused patients . | No. of evaluable patients . | No. in complete remission . | No. in partial remission . |
|---|---|---|---|---|
| CML/CMML | 4 | 4 | 2 | 2 |
| AML | 9 | 5 | 1* | 1 |
| ALL | 2 | 1 | 0 | 0 |
| NHL | 4 | 3 | 2 | 1 |
| HD | 2 | 2 | 0 | 0 |
| MM | 2 | 2 | 1 | 1 |
| Total | 23 | 17 | 6 | 5 |
| Diagnosis . | No. of infused patients . | No. of evaluable patients . | No. in complete remission . | No. in partial remission . |
|---|---|---|---|---|
| CML/CMML | 4 | 4 | 2 | 2 |
| AML | 9 | 5 | 1* | 1 |
| ALL | 2 | 1 | 0 | 0 |
| NHL | 4 | 3 | 2 | 1 |
| HD | 2 | 2 | 0 | 0 |
| MM | 2 | 2 | 1 | 1 |
| Total | 23 | 17 | 6 | 5 |
Patients were evaluable for graft-versus-tumor (GvT) activity if surviving more than 30 days after infusion of TK-DLI. Clinical response was graded according to criteria described in “Patients, materials, and methods”.
Abbreviations are explained in Table 1.
Patient received debulking chemotherapy.